Nexvet
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly
R35 FR98
Tel: 1-415-375-3340
Fax: n/z
Website: http://ir.nexvet.com/
About Nexvet
Nexvet is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.YEAR FOUNDED:
2010
LEADERSHIP:
CEO: Mark Heffernan
CSO: David Gearing
CFO: Damian Lismore
CPO: Jurgen Horn
JOBS:
Please click here for Nexvet job opportunities.
13 articles about Nexvet
-
Zoetis Completes Acquisition Of Nexvet
7/31/2017
-
Nexvet Rule 17(d) Announcement
7/28/2017
-
Nexvet Rule 17(c) Announcement
7/10/2017
-
Nexvet Rule 2.10 Announcement
7/5/2017
-
Nexvet Release: Rule 15 Announcement
6/16/2017
-
Nexvet Rule 17(b) Announcement
6/7/2017
-
Nexvet Rule 17 Announcement
6/2/2017
-
Nexvet Rule 2.10 Announcement
5/12/2017
-
Nexvet Reports Financial Results For Third Quarter Of Fiscal Year 2017
5/11/2017
-
Nexvet Stock Skyrockets on $85 Million Takeover Offer from Zoetis
4/14/2017
-
Nexvet Announces Initiation Of Pivotal Efficacy Study Of Frunevetmab In Cats
12/12/2016
-
Nexvet Reports Financial Results For First Quarter Of Fiscal Year 2017
11/4/2016
-
Nexvet Reports Full Year Fiscal 2016 Results
9/2/2016